National and Kapodistrian University of Athens
Φαρμακευτική παρέμβαση στις μεταβολικές και ορμονικές διαταραχές και στους δείκτες καρδιαγγειακού κινδύνου στις γυναίκες με σύνδρομο πολυκυστικών ωοθηκών
Abstract
dc:descriptionBackground : Current knowledge on the pathophysiology of polycystic ovary syndrome (PCOS) has created a new framework for the treatment of the syndrome, which includes the need for amelioration of atherogenic markers which may be elevated in women with the syndrome. The costs and benefits of two most commonly prescribed pharmaceutical treatments in PCOS, oral contraceptives (OCPs) and metformin have been studied in this framework. Metformin appears to alleviate the cardiovascular risk associated with PCOS, while OCPs may have a neutral or aggravating effect on atherogenic markers.Objective: The present work compares the effects of two types of OCPs and metformin on atherogenic markers, including serum levels of Advanced Glycated End products (AGEs) and C-reactive protein (CRP), in lean women with PCOS.Design: Prospective open-label study Results: One hundred and twenty women with PCOS were treated for six months with one of the following treatments: ethinylestradiol plus cyproterone acetate (OCP 1) or ethinylestradiol plus drospirenone (OCP2) or metformin (MET). The three groups were matched for age and body mass index (BMI). At six months serum AGEs were decreased in all groups, but the decrease was greater with metformin. Treatment with metformin was associated with a greater percent decrease of AGEs. CRP was decreased with metformin, but increased with OCPs, to a greater degree with OCP1 compared to OCP2. Conclusions: This study attempts to evaluate common therapeutic options in women with PCOS by reconsidering and prioritizing the goals of treatment. OCPs and metformin appear to have differential effects on atherogenic molecules in lean PCOS patients, but metformin was superior in reducing serum AGEs and CRP. Clinicians should individualise the benefit-to-risk ratio of pharmaceutical intervention in women with PCOS, in order to choose the formulation with the greatest efficacy and safety in terms of cardiovascular risk.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2013
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Christakou, Charikleia
- Χρηστάκου, Χαρίκλεια
Subjects
dc:subject × 16- Σύνδρομο πολυκυστικών ωοθηκών
- Δείκτες καρδιαγγειακού κινδύνου
- Αθηρογόνα μόρια
- Αντισυλληπτικά δίσκια
- Μετφορμίνη
- Τελικά προϊόντα προχωρημένης γλυκοζυλίωσης
- Polycystic Ovary Syndrome
- Cardiovascular risk markers
- Atherogenic molecules
- Oral contraceptives
- Metformin
- Advanced glycated end products
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/38496